191 related articles for article (PubMed ID: 33909826)
1. Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes.
Ravanini JN; Assato AK; Wakamatsu A; Alves VAF
Clinics (Sao Paulo); 2021; 76():e2587. PubMed ID: 33909826
[TBL] [Abstract][Full Text] [Related]
2. Stratification of urothelial bladder carcinoma depending on immunohistochemical expression of GATA3 and CK5/6.
Serag Eldien MM; Abdou AG; Elghrabawy GRA; Alhanafy AM; Mahmoud SF
J Immunoassay Immunochem; 2021 Nov; 42(6):662-678. PubMed ID: 34106817
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.
Sikic D; Keck B; Wach S; Taubert H; Wullich B; Goebell PJ; Kahlmeyer A; Olbert P; Isfort P; Nimphius W; Hartmann A; Giedl J;
PLoS One; 2017; 12(6):e0179602. PubMed ID: 28632777
[TBL] [Abstract][Full Text] [Related]
4. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype.
Rebola J; Aguiar P; Blanca A; Montironi R; Cimadamore A; Cheng L; Henriques V; Lobato-Faria P; Lopez-Beltran A
Virchows Arch; 2019 Oct; 475(4):445-455. PubMed ID: 31240474
[TBL] [Abstract][Full Text] [Related]
5. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
[TBL] [Abstract][Full Text] [Related]
6. Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Bruch PG; Plage H; Hofbauer S; Kornienko K; Weinberger S; Roßner F; Schallenberg S; Kluth M; Lennartz M; Blessin NC; Marx AH; Samtleben H; Fisch M; Rink M; Slojewski M; Kaczmarek K; Ecke T; Hallmann S; Koch S; Adamini N; Minner S; Simon R; Sauter G; Zecha H; Klatte T; Schlomm T; Horst D; Elezkurtaj S
Exp Mol Pathol; 2023 Jun; 131():104860. PubMed ID: 36997051
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
8. Prognostic stratification of muscle invasive urothelial carcinomas using limited immunohistochemical panel of Gata3 and cytokeratins 5/6, 14 and 20.
Jangir H; Nambirajan A; Seth A; Sahoo RK; Dinda AK; Nayak B; Kaushal S
Ann Diagn Pathol; 2019 Dec; 43():151397. PubMed ID: 31494492
[TBL] [Abstract][Full Text] [Related]
9. FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma.
Warrick JI; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff D; Chen G
Virchows Arch; 2017 Sep; 471(3):337-345. PubMed ID: 28721490
[TBL] [Abstract][Full Text] [Related]
10. Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
Kim JM; Choi E; Sung SH; Kang H; Park S
Pathol Res Pract; 2023 Nov; 251():154839. PubMed ID: 37801908
[TBL] [Abstract][Full Text] [Related]
11. A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.
Bontoux C; Rialland T; Cussenot O; Compérat E
Virchows Arch; 2021 Apr; 478(4):637-645. PubMed ID: 33128085
[TBL] [Abstract][Full Text] [Related]
12. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast activation protein (FAP) expression in CK5/6 expressed (Basal subtype) & CK20 expressed (Luminal subtype) urothelial bladder carcinoma: an immunohistochemical study.
Hemida AS; Aiad HAES; Hassan NA; Al Sharaky DR
J Immunoassay Immunochem; 2022 Nov; 43(6):618-633. PubMed ID: 35787739
[TBL] [Abstract][Full Text] [Related]
14. Nested Variant of Urothelial Carcinoma Is a Luminal Bladder Tumor With Distinct Coexpression of the Basal Marker Cytokeratin 5/6.
Johnson SM; Khararjian A; Legesse TB; Khani F; Robinson BD; Epstein JI; Wobker SE
Am J Clin Pathol; 2021 Mar; 155(4):588-596. PubMed ID: 33118597
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
[TBL] [Abstract][Full Text] [Related]
16. Invasive urothelial carcinoma exhibiting basal cell immunohistochemical markers: A variant of urothelial carcinoma associated with aggressive features.
Mai KT; Truong LD; Ball CG; Williams P; Flood TA; Belanger EC
Pathol Res Pract; 2015 Aug; 211(8):610-8. PubMed ID: 26100813
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic and Immunohistochemical Study of Combined Small Cell Carcinoma and Urothelial Carcinoma Molecular Subtype.
Xiao GQ; Barrett MM; Yang Q; Unger PD
Pathol Oncol Res; 2019 Jul; 25(3):889-895. PubMed ID: 29249035
[TBL] [Abstract][Full Text] [Related]
18. A deep-learning workflow to predict upper tract urothelial carcinoma protein-based subtypes from H&E slides supporting the prioritization of patients for molecular testing.
Angeloni M; van Doeveren T; Lindner S; Volland P; Schmelmer J; Foersch S; Matek C; Stoehr R; Geppert CI; Heers H; Wach S; Taubert H; Sikic D; Wullich B; van Leenders GJ; Zaburdaev V; Eckstein M; Hartmann A; Boormans JL; Ferrazzi F; Bahlinger V
J Pathol Clin Res; 2024 Mar; 10(2):e12369. PubMed ID: 38504364
[TBL] [Abstract][Full Text] [Related]
19. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
[TBL] [Abstract][Full Text] [Related]
20. Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer.
Bejrananda T; Kanjanapradit K; Saetang J; Sangkhathat S
Sci Rep; 2021 Oct; 11(1):21186. PubMed ID: 34707176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
